Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study | Zendy

Sharat Chandra | Zendy; Tsuyoshi Fukuda | Zendy; Kana Mizuno | Zendy; Stella M. Davies | Zendy; Ashley TeusinkCross | Zendy; Rich Tarin | Zendy; Rebecca Marsh | Zendy; Alexander A. Vinks | Zendy; Parinda A. Mehta | Zendy

Open Access

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study

Author(s) -

Sharat Chandra,

Tsuyoshi Fukuda,

Kana Mizuno,

Stella M. Davies,

Ashley TeusinkCross,

Rich Tarin,

Rebecca Marsh,

Alexander A. Vinks,

Parinda A. Mehta

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky030

Subject(s) - micafungin , dosing , pharmacokinetics , medicine , population , toxicity , pharmacology , anesthesia , antifungal , fluconazole , environmental health , dermatology

Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is given as either 1 mg/kg every day or 3 mg/kg every other day.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research